Eight children underwent reduced-intensity stem cell transplantation (RIST) from an HLA-matched sibling. They received a fludarabine-melphalan based preparative regimen. Stem cell source was bone marrow, and GVHD prophylaxis consisted of cyclosporine A alone. Acute GVHD grade II-IV and grade III-IV were observed in four (50%) and three (37.5%), respectively, out of these eight patients. This incidence was significantly higher than that after conventional bone marrow transplantation, without severe tissue damage, in the same setting of stem cell source and GVHD prophylaxis. Although the number of patients is small, our results suggest that incidence of acute GVHD after RIST for children is significant. It should be remembered that RIST for children does not seem to be an easy transplant procedure from the viewpoint of acute GVHD, although RIST is less toxic.
Introduction
Reduced-intensity stem cell transplantation (RIST) has been performed mainly for elderly patients or those with severe comorbidity who are not candidates for conventional stem cell transplantation (CST). It expands the opportunity for use of transplantation and avoids transplant-related morbidity. [1] [2] [3] [4] [5] [6] [7] For pediatric patients, RIST can be used to avoid not only the early toxic effects of transplantation but also late effects, as the children grow and develop into adults. Although there have been many publications about RIST for adult patients, few reports describing RIST for children have been published to date. [8] [9] [10] [11] The outcome of RIST for children remains to be clarified.
The rationale of RIST for malignant diseases is based on a comparison of the immunological effects of donorderived immunocompetent cells with the cytotoxic effect of profoundly cytoreductive preparative regimens. [12] [13] [14] [15] [16] [17] [18] However, differentiation of a graft-versus-leukemia effect or graft-versus-tumor effect from GVHD is difficult. Acute GVHD is one of the major complications after transplant caused by the reaction between recipient-derived antigenpresenting cells (APCs) and donor-derived T-lymphocytes in the context of hypercytokinemia due to tissue damage. 19, 20 RIST causes less tissue damage and less cytokine release, but it also permits the survival of many more recipient-derived APCs than CST. From this perspective, acute GVHD after RIST has received attention, and many reports describing acute GVHD after RIST for adult patients have been published. [21] [22] [23] [24] However, definitive conclusions have not yet been drawn. In our experience, the risk of acute GVHD after RIST for children is significant. We therefore describe the characteristics of acute GVHD in children after RIST from an HLAmatched sibling compared with those after CST in a retrospective analysis from a single institute.
Patients and methods
Between January 2001 and January 2005, 54 children received RIST using various sources of stem cells, for the treatment of malignant or nonmalignant diseases, at the Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan. Among these patients, eight received bone marrow from an HLA-matched sibling as the first transplant ( Table 1 ). The median age at transplant was 5 years 8 months (range 3 months-9 years eight months). Two had AML, one had JMML, one had chronic active EBV infection, one had familial hemophagocytic lymphohistiocytosis, two had congenital immunodeficiency and one had a congenital bone marrow failure syndrome. Conventional bone marrow transplantation (BMT) from HLA-matched sibling as the first allogeneic transplant was performed for 33 children who received GVHD prophylaxis with CSA alone, between November 1994 and January 2005. Only one patient died of sepsis on day 32 after transplant without any symptoms of acute GVHD. The remaining 32 of these 33 patients survived beyond day 100 with engraftment and were suitable for evaluation of acute GVHD. The majority of these 32 patients suffered from a malignant disease, and the median age at Immunodeficiency  0  0  0  0  -320  6Y1M  FHL  I  1  0  0  59  331  6Y4M  Immunodeficiency  I  1  0  0  42  371  0Y3M  CAEBV  I  2  0  0  44  343  3Y9M  CBMFS  II  3  0  1  12  385  5Y2M  JMML  III  2  0  4  19  402  1Y0M  AML  III  2  0  4  48  396  9Y8M  AML  IV  4  0  3  19 CST group 1 (mild tissue damage): n ¼ 15 I  1  0  0  13  240  1Y7M  ALL  I  2  0  0  15  236  10Y3M  AML  I  2  0  0  11  261  10Y6M  AML  II  3  0  0  11  71  11Y7M  ALL  II  3  1  0  10  79  16Y0M  Neuroblastoma  II  3  0  0  9  120  2Y0M  Neuroblastoma  II  1  0  1  7  136  0Y9M  JMML  II  3  0  0  13  196  7Y8M  NHL  III  3  0  3  9  110  10Y6M  AML  III  3  0  3  33  128  12Y6M  AMLL  III  1  0  4  13  216  9Y1M  ALL  III  3  0  2  12  220  14Y4M  CGD  III  0  0  4  19  232  6Y11M  Neuroblastoma  III  3  0  3  9 RIST ¼ reduced-intensity stem cell transplantation; CST ¼ conventional stem cell transplantation; FHL ¼ familial hemophagocytic lymphohistiocytosis; CAEBV ¼ chronic active EBV infection; CBMFS ¼ congenital bone marrow failure syndrome; JMML ¼ juvenile myelomonocytic leukemia; AML ¼ acute myelogenous leukemia; ALL ¼ acute lymphoblastic leukemia; CMMoL ¼ chronic myelomonocytic leukemia; AMLL ¼ acute mixed lineage leukemia; NHL ¼ non-Hodgkin lymphoma; CGD ¼ chronic granulomatous disease; CTCAE ¼ Common Terminology Criteria for Adverse Events ver. 3.0. Patients who had diarrhea or mucositis as a regimen related toxicity less than grade 2 are included in the CST group 1 (mild tissue damage). Patients who had diarrhea or mucositis as a regimen related toxicity equal or more than grade 2 are included in the CST group 2 (severe tissue damage).
Acute graft-versus-host disease after RIST for children M Inoue et al transplantation was 7 years and 7 months (range 5 months-16 years). We divided the patients who underwent CST into two groups according to the intensity of tissue damage (Table 1) . Patients who developed diarrhea or mucositis as a regimenrelated toxicity less than grade 2 were included in CST group 1 (mild tissue damage). Patients who had diarrhea or mucositis equal or more than grade 2 were included in the CST group 2 (severe tissue damage). None of the patients who received RIST developed diarrhea or mucositis more than grade 1. Diarrhea and mucositis were graded according to the Common Terminology Criteria for Adverse Events ver. 3.0 (CTCAE) published by the National Cancer Institute (NCI) in December 2003. We evaluated the incidence and intensity of acute GVHD, comparing RIST and CST by BMT from an HLA-matched sibling with the same method of GVHD prophylaxis using CSA alone to examine the impact of tissue damage on acute GVHD. The intensity of acute GVHD was graded according to the consensus criteria. 25 Incidence of acute GVHD was calculated using the Kaplan-Meier method, and the log-rank test was used for comparison of curves. All statistical analyses were done using SAS ver. 8.2.
Results
There was a significant difference in the incidence of acute GVHD between the three groups that underwent CST or RIST (Figure 1 . P-value ¼ 0.0003 for grade II-IV and Pvalue ¼ 0.0023 for grade III-IV). Among the eight patients who underwent RIST, acute GVHD grade II-IV and grade III-IV was observed in four (50%) and three (37.5%), respectively, whereas there was only one (6.7%) and none (0%), respectively, among 15 patients in the CST group 1 (mild tissue damage) and 11 (64.7%) and six (35.3%), respectively, among 17 patients in the CST group 2 (severe tissue damage). Severe acute GVHD (grade III-IV) involved an advanced stage of skin GVHD, and especially gut GVHD without liver involvement, in these patients.
Concerning chronic GVHD in the RIST group, two patients, UPN 385 and 402, developed extensive chronic GVHD after grade III acute GVHD. None of the eight patients developed serious infection after RIST.
Discussion
Among patients who underwent CST, there was much more frequent and more severe acute GVHD in recipients with severe tissue damage (CST group 2) compared to the situation in recipients with mild tissue damage (CST group 1). This result was expected when considering hypercytokinemia followed by tissue damage due to the preparative regimen. However, the incidence of acute GVHD after RIST was contrary to our expectations and was higher than that seen with CST group 1 (mild tissue damage). Nevertheless, neither of these two groups (RIST group and CST group 1) experienced more than grade 1 diarrhea or mucositis. The higher incidence of acute GVHD observed in patients undergoing RIST is said to be enhanced by factors other than tissue damage. Cross reaction between recipient-derived APCs surviving after RIST and donorderived T-lymphocytes might play an important role in the pathogenesis of acute GVHD.
The incidence and intensity of acute GVHD after RIST remains controversial. [21] [22] [23] [24] Less tissue damage compared to that after CST, mixed chimerism and the use of a regimen containing ATG may induce a lower incidence of acute GVHD in RIST. After reviewing recent reports, the incidence of GVHD after RIST does not seem to be higher than that seen after CST.
Few reports are available relating to pediatric experiences to date. Amrolia et al. 8 reported that none of the eight patients developed significant acute GVHD after nonmyeloablative SCT for congenital immunodeficiences. Six patients received BM from an HLA-matched unrelated donor and two received BM from an HLA-matched sibling. GVHD prophylaxis consisted of CSA and methylprednisolone. Del Toro et al. 9 performed RIST for 21 children with malignant or nonmalignant diseases. In their series, six patients out of 21 (21.6%) developed grade II or III acute GVHD. Stem cell sources varied from unrelated cord blood to BM or peripheral blood from an HLA-matched family donor. GVHD prophylaxis consisted of tacrolimus and mycophenolate mofetil. Jacobsohn, et al.
10 performed RIST for 13 pediatric patients with nonmalignant disorders. The incidence of grade II-IV acute GVHD was 8%. Eleven patients received peripheral blood stem cells from a sibling or unrelated donor. GVHD prophylaxis consisted of CSA. Mycophenolate mofetil was added for six patients. The incidence of acute GVHD after RIST for children in Acute graft-versus-host disease after RIST for children M Inoue et al these reports does not appear significant and differs from our experience. Contrary to previous reports, the incidence and intensity of acute GVHD in our series were considerable.
Many factors are associated with the development of acute GVHD, and it is not easy to ascertain why our experience differs from previous reports. However, this is the first report evaluating acute GVHD after RIST compared with the outcome of CST using the same stem cell source and GVHD prophylaxis, namely BMT from an HLA-matched sibling and CSA alone, and focusing on the contribution of tissue damage to acute GVHD in children. Although the number of patients is small, our findings suggest that the intensity of tissue damage is positively related to the incidence and intensity of acute GVHD after CST. The incidence of acute GVHD after RIST is significant although conditioning for RIST involves a less toxic regimen. It should be remembered that RIST for children may be problematic from the perspective of acute GVHD although RIST is a less toxic transplant procedure than CST.
